文献速递肝病消化道肿瘤与早癌

肝硬化患者肝细胞癌监测的获益与危害:一项前瞻性队列研究

Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-10

该研究为一项临床试验的二次分析,纳入614例肝硬化患者,评估肝细胞癌监测的获益(早期检出和接受治愈性治疗)与物理危害(假阳性或不确定结果的诊断操作)。监测检出肝细胞癌者BCLC 0/A期比例和治愈性治疗率与偶然/症状诊断者无显著差异,物理危害轻微。

要点

  • 614例肝硬化患者中118例(19.2%)监测结果异常,26例发生肝细胞癌,其中16例(61.5%)由监测检出。
  • 监测检出者BCLC 0/A期比例为62.5%,偶然/症状诊断者为50%,两组无显著差异(p=.69)。
  • 监测检出者接受治愈性治疗比例为43.8%,偶然/症状诊断者为40.0%,两组无显著差异(p=1.0)。

核心结论

  • 在该肝硬化队列中,肝细胞癌监测与高早期肿瘤检出率和极小的物理危害相关。

研究设计与样本

  • 对一项评估肝硬化患者肝细胞癌监测的临床试验进行二次分析,纳入2014年12月至2015年7月期间在安全网卫生系统入组的肝硬化患者。
  • 共纳入614例至少接受1次监测检查的肝硬化患者,评估18个月期间的监测相关获益和物理危害。

主要发现

  • 614例患者中118例(19.2%)监测结果异常。
  • 随访期间26例发生肝细胞癌,其中16例(61.5%)由监测检出。
  • 监测检出者BCLC 0/A期比例为62.5%,偶然/症状诊断者为50%,两组无显著差异(p=.69)。
  • 监测检出者接受治愈性治疗比例为43.8%,偶然/症状诊断者为40.0%,两组无显著差异(p=1.0)。
  • 54例(8.8%)接受监测的患者出现物理危害,多数为轻度,仅1例接受诊断性CT或MRI,无患者接受活检等侵入性检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The value of a cancer screening programs is defined by its balance of benefits and harms; however, there are few data evaluating both attributes for hepatocellular carcinoma (HCC) surveillance. We aimed to characterize benefits and harms of HCC surveillance in a large prospective cohort of patients with cirrhosis. METHODS: We conducted a secondary analysis of a clinical trial evaluating HCC surveillance among patients with cirrhosis at a safety-net health system enrolled between December 2014 and July 2015. We quantified surveillance-related benefits, defined as early HCC detection and curative treatment receipt, and physical harms, defined as diagnostic procedures for false positive or indeterminate results, over an 18-month period. RESULTS: Of 614 cirrhosis patients with ≥1 surveillance exam, abnormal results were observed in 118 (19.2%) patients. Twenty-six patients developed HCC during follow-up, of whom 16 (61.5%) were detected by surveillance. The proportion of HCC detected at BCLC stage 0/A (62.5% vs 50%, p = .69) and who underwent curative treatment (43.8% vs. 40.0%, p = 1.0) did not significantly differ between surveillance-detected patients and those diagnosed incidentally/symptomatically. Physical harms were observed in 54 (8.8%) patients who underwent surveillance - most of mild severity with only 1 diagnostic CT or MRI and none undergoing invasive testing such as biopsy. Incidental findings on follow-up imaging were found in 40 (6.5%) patients -23 of low clinical importance and 17 medium clinical importance. CONCLUSIONS: In our cohort of patients with cirrhosis, HCC surveillance was associated with high early tumor detection and minimal physical harms.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singal AG, Patibandla S, Obi J, et al. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020. PMID: 32920214. doi:10.1016/j.cgh.2020.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。